| The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non–small cell lung cancer: A multicenter retrospective cohort study | | 2022 |
| Safety and efficacy of pralsetinib in RET fusion–positive non-small cell lung cancer including as first-line therapy: update from the ARROW trial | | 2022 |
| Role of Stereotactic Radiation Therapy in Operable and Inoperable Early-Stage Non-small Cell Lung Cancer | | 2022 |
| Evaluation of the synergistic impact of needle and forceps biopsy with electromagnetic navigation bronchoscopy: the CONFIDENT-ENB trial design | | 2022 |
| Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial | | |
| Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial | | 2022 |
| Characterizing the Shifting Real-World Treatment Landscape by PD-L1 Testing Status and Expression Level in Advanced Non-Small Cell Lung Cancer | | |
| EGFR-mutant NSCLC: monitoring the molecular evolution of tumors in 2022 | | |
| Survival benefits of primary tumor surgery for synchronous brain metastases: A SEER ‐based population study with propensity‐matched comparative analysis | | |
| Crizotinib Efficacy After Progression With Entrectinib in ROS1-Positive Lung Cancer: A Case Report | | 2022 |
| Older Patients with Lung Cancer: a Summary of Seminal Contributions to Optimal Patient Care | | |
| Multi-Gene Mutation Profiling by Targeted Next-Generation Sequencing in Premenopausal Breast Cancer | | 2022 |
| Role of Radiologic Imaging in Lung Cancer | | 2022 |
| Malignancies in HIV | | 2021 |
| Expert opinion on NSCLC small specimen biomarker testing — Part 1: Tissue collection and management | Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin | |
| The Association between Muscle Quantity and Overall Survival Depends on Muscle Radiodensity: A Cohort Study in Non-Small-Cell Lung Cancer Patients | Journal of Personalized Medicine | 2022 |
| Practical considerations of single-fraction stereotactic ablative radiotherapy to the lung | Lung Cancer | 2022 |
| Long-term survival of patients with central or > 7 cm T4 N0/1 M0 non-small-cell lung cancer treated with definitive concurrent radiochemotherapy in comparison to trimodality treatment | Radiation Oncology | 2022 |
| Molecular biomarkers and liquid biopsies in lung cancer | Seminars in Oncology | 2022 |
| A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC) | Expert Opinion on Pharmacotherapy | |
| Disparate Access to Surgery for Operable Carcinoma of the Lung in North Carolina | Annals of Surgical Oncology | |
| Prognostic significance of location index in resected T1-sized early-stage non-small cell lung cancer | Acta Radiologica | |
| Postoperative tegafur–uracil for stage I lung adenocarcinoma: first real-world data with an exploratory subgroup analysis | Surgery Today | |
| Variants of ERCC5 and the outcome of platinum-based regimens in non-small cell lung cancer: a prospective cohort study | | 2022 |
| Pulmonary Segmentectomy: A New Standard of Care in Patients with Non-Small Cell Cancer | Journal of Cardiothoracic and Vascular Anesthesia | 2022 |
| Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer | Current Oncology | 2022 |
| Real-World Clinical Outcomes after Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer | Current Oncology | 2022 |
| Rationale for Combing Stereotactic Body Radiation Therapy with Immune Checkpoint Inhibitors in Medically Inoperable Early-Stage Non-Small Cell Lung Cancer | Cancers | 2022 |
| The Impact of Enhanced Recovery After Surgery on Persistent Opioid Use Following Pulmonary Resection | Annals of Thoracic Surgery | 2022 |
| Low-dose computed tomography screening, follow-up, and management of lung nodules – An expert consensus statement from Taiwan | Formosan Journal of Surgery | 2022 |
| Circulating cancer biomarkers: current status and future prospects | | 2022 |
| Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States | Journal of Medical Economics | 2022 |
| Immune Checkpoint Inhibitors and Chemoradiation for Limited-Stage Small Cell Lung Cancer | Current Treatment Options in Oncology | |
| Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC | Clinical Medicine Insights: Oncology | 2022 |
| Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50% | Therapeutic Advances in Medical Oncology | 2022 |
| Three-port single-intercostal versus uniportal thoracoscopic segmentectomy for the treatment of lung cancer: a propensity score matching analysis | World Journal of Surgical Oncology | 2022 |
| Targeting EGFR Exon 20 Insertion Mutation in Non–small cell Lung Cancer: Amivantamab and Mobocertinib | Annals of Pharmacotherapy | |
| Lack of an association between marital status and survival in patients receiving stereotactic body radiotherapy for early-stage non-small-cell lung cancer | PLoS ONE | 2022 |
| Development and validation of a computed tomography–based immune ecosystem diversity index as an imaging biomarker in non-small cell lung cancer | European Radiology | |
| Salvage surgery for local recurrence after sublobar surgery in Stages I and II non‐small cell lung cancer | Journal of Surgical Oncology | |
| Association of Diabetes Severity and Mortality with Lung Squamous Cell Carcinoma | Cancers | 2022 |
| FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer Patients | Seminars in Nuclear Medicine | 2022 |
| Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA | Cancers | 2022 |
| All EGFR mutations are (not) created equal: focus on uncommon EGFR mutations. | Journal of Cancer Research and Clinical Oncology | 2022 |
| Allele frequency and proportion defined by circulating tumor DNA profiling predict tyrosine kinase inhibitors' therapeutic outcomes for non-small cell lung cancer. | Journal of Cancer Research and Clinical Oncology | 2022 |
| Development and validation of ACTE-MTB: A tool to systematically assess the maturity of molecular tumor boards. | PLoS ONE | 2022 |
| Use of the Biocartis Idylla™ Platform for the Detection of Epidermal Growth Factor Receptor, BRAF and KRAS Proto-Oncogene Mutations in Liquid-Based Cytology Specimens from Patients with Non-Small Cell Lung Carcinoma and Pancreatic Adenocarcinoma | Journal of Molecular Pathology | 2022 |
| Oncological Diseases | | 2022 |
| BRAF in lung cancer: A narrative review | Cancer Research Statistics and Treatment | 2021 |
| Patient perception of burden of disease and treatment preferences in non-small cell lung cancer: Results from a European survey. | Lung Cancer | 2022 |
